Continuous glucose monitoring worth $1.2 billion to Abbott
This article was originally published in Clinica
Abbott Laboratories has offered $1.2bn in cash for TheraSense, a developer and marketer of glucose monitors. Although Abbott has its own MediSense range of blood glucose monitors for diabetic patients, it is keen to establish a position in the next generation of these products, which are seeing a greater focus on reduced pain and continuous measurement.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.